Compare ProShares UltraPro QQQ ETF (TQQQ) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro QQQ ETF vs 10X Genomics Inc — how do they compare? ProShares UltraPro QQQ ETF trades at $81.28 (market cap $38.74B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: ProShares UltraPro QQQ ETF is far larger — about 3.8× 10X Genomics Inc's market cap, and ProShares UltraPro QQQ ETF is more actively traded (65,384,797 versus 5,657,286). Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraPro QQQ ETF for 24 Days and 10X Genomics Inc for 91 Days on average.
| TQQQ | TXG | |
|---|---|---|
Market Cap | $38.74B | $10.07B |
Volume | 65,384,797 | 5,657,286 |
Sector | Leveraged / Inverse | Health |
52-Week High | $87.22 | $97.74 |
52-Week Low | $37.89 | $11.48 |
Typical Hold Time | 24 Days | 91 Days |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TQQQ trades at $80.22, down 4.04% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF's 3x leverage amplifies Nasdaq-100 moves, yet hidden costs like financing charges impact returns. Recent news highlights volatility risks and institutional position changes, while support sits at $78 and resistance at $83.
Outlook remains mixed: bullish technicals and AI-driven tech growth offer upside, but leverage decay and market volatility pose significant risks. Investors face amplified losses in downturns, warranting caution despite short-term momentum opportunities.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
